Incretin-Based Therapies: Review of Current Clinical Trial Data

American Journal of Medicine

Volumn 123, Issue 3 SUPPL., 2010, Pages

  Peters, Anne ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Exenatide; GIP; GLP 1; Incretin; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; AVE 0010; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; R 1583; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CALORIC INTAKE; CLINICAL ASSESSMENT; DIARRHEA; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; INSULIN RELEASE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SKIN MANIFESTATION; STOMACH EMPTYING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIGENS, CD26; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PEPTIDES; PYRAZINES; RECEPTORS, GLUCAGON; TRIAZOLES; VENOMS;

EID: 77449094873     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.12.007     Document Type: Article

References (66)

1. Elrick H., Stimmler L., Hlad C.J., and Ari Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24 (1964) 1076-1082
2. Nauck M.A., Homberger E., Siegel E.G., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol 63 (1986) 492-498
3. Drucker D.J. The biology of incretin hormones. Cell Metab 3 (2006) 153-165
4. Buchan A.M., Polak J.M., Capella C., Solcia E., and Pearse A.G. Electroimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 56 (1978) 37-44
5. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amid] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 (1993) 301-307
6. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 21 (2007) 517-533
7. Nauck M.A., Niedereichholzs U., Ettler R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273 (1997) E981-E988
8. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
9. Buteau J., Foisy S., Rhodes C.J., Carpenter L., Biden T.J., and Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes 50 (2001) 2237-2243
10. Kolligs F., Fehmann H.C., Goke R., and Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amid. Diabetes 44 (1995) 16-19
11. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., and Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 (1995) 1126-1131
12. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2007) 194-206
13. Stonehouse A., Okerson T., Kendall D., and Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 4 (2008) 101-109
14. Jackson E.K., and Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 51 (2008) 1637-1642
15. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267 (1992) 7402-7405
16. Byetta (exenatide injection) [package insert] (2008), Amylin Pharmaceuticals, Inc, San Diego, CA
17. Kolterman O.G., Buse J.B., Fineman M.S., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 3082-3089
18. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm 62 (2005) 173-181
19. Szayna M., Doyle M.E., Betkey J.A., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
20. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
21. Bunck M.C., Diamant M., Cornér A., et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32 (2009) 762-768
22. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., and Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
23. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
24. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
25. American Diabetes Association. Standards of medical care. Diabetes Care 32 suppl 1 (2009) S13-S61
26. Zinman B., Hoogwerf B.J.D.G.S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 146 (2007) 477-485
27. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24 (2008) 275-286
28. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., and Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
29. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G., and Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 (2006) 2638-2643
30. Rosenstock J., Brazg R., Andryuk P.J., Lu K., Stein P., and Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 (2006) 1556-1568
31. Blonde L., Klein E.J., Han J., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
32. Balani A.R., and Grendell J.H. Drug-induced pancreatitis: incidence, management and prevention. Drug Safety 31 (2008) 823-837
33. Noel R.A., Braun D.K., Patterson R.E., and Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective, cohort study. Diabetes Care 32 (2009) 834-838
34. Idris I. FDA reviews incidences of acute pancreatitis in patients taking Byetta. Diabetes Obes Metab 10 (2008) 96-98
35. Dore D.D., Seeger J.D., and Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25 (2009) 1019-1027
36. Januvia (sitagliptin) [package insert] (2007), Merck & Co., Inc, Whitehouse Station, NJ
37. Herman G.A., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91 (2006) 4612-4619
38. US Food and Drug Administration. Information for Healthcare Professionals: acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) (September 25, 2009). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm Accessed November 3, 2009
39. Matveyenko A.V., Dry S., Cox H.I., et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58 (2009) 1604-1615
40. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., and MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24 (2008) 2943-2952
41. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 32 suppl 1 (2009) S62-S67
42. 1c. Endocr Pract 12 suppl 1 (2006) 42-46
43. Kim D., MacConell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30 (2007) 1487-1493
44. Drucker D.J., Buse J.B., Taylor K., et al., DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 372 (2008) 1240-1250
45. Bergenstal R, Kim T, Trautmann M, et al. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes. In: Program and Abstracts of the American Heart Association Scientific Sessions; November 9, 2008; New Orleans, Louisiana. Abstract 1239.
46. Young A.A., Gedulin B.R., Bhavsar S., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48 (1999) 1026-1034
47. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., et al. Potent derivatives of glucagon-like peptide 1 with pharmacokinetic properties suitable for once-daily administration. J Med Chem 43 (2000) 1664-1669
48. European Medicines Agency. Committee for Medicinal Products for Human Use Summary of Positive Opinion for Victoza, international nonproprietary name (INN): liraglutide (April 23, 2009). http://www.emea.europa.eu/pdfs/human/opinion/Victoza_14168909en.pdf Accessed July 1, 2009
49. Marre M., Shaw J., Brandle M., et al., LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26 (2009) 268-278
50. Nauck M., Frid A., Hermansen K., et al., LEAD-2 Metformin Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 32 (2009) 84-90
51. Agerso H., and Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 19 (2003) 141-150
52. Garber A., Henry R., Ratner R., et al., LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009) 473-481
53. Zinman B., Gerich J., Buse J.B., et al., LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32 (2009) 1224-1230
54. Russell-Jones D., Vaag A., Schmitz O., et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. Diabetes 57 (2008) A159-A160 Abstract 536-P
55. Buse J.B., Rosenstock J., Sesti G., et al., LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 (2009) 39-47
56. Madsbad S. Liraglutide effect and action in diabetes (LEAD) trial. Expert Rev Endocrinol Metab 4 (2009) 119-129
57. Endocrine and Metabolic Drug Advisory Committee. Liraglutide (injection) for the treatment of patients with type 2 diabetes. Novo Nordisk, Inc. NDA 22-341. Briefing document (April 2, 2009). http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-02-NovoNordisk.pdf Accessed November 3, 2009
58. US Food and Drug Administration. Liraglutide. Briefing materials (April 2, 2009). http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf Accessed November 3, 2009
59. Nauck M.A., Ratner R.E., Kapitza C., Berria R., Boldrin M., and Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 32 (2009) 1237-1243
60. Distiller L.A., and Ruus P. Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients. Program and Abstracts of the 68th Scientific Sessions of the American Diabetes Association. June 6-10, 2008; San Francisco, California (2008) A154-A155 Abstract 520-P
61. Matthews J.E., Stewart M.W., De Boever E.H., et al., Albiglutide Study Group. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 93 (2008) 4810-4817
62. Davidson J.A., Parente E.B., and Gross J.L. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arq Bras Endocrinol Metabol 52 (2008) 1039-1049
63. Ferrannini E., Fonseca V., Zinman B., et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11 (2009) 157-166
64. Rosenstock J., Sankoh S., and List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 10 (2008) 376-386
65. Feng J., Zhang Z., Wallace M.B., et al. Discovery of alogliptin: a potent, selective bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50 (2007) 2297-2300
66. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekke Q., and Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31 (2008) 2315-2317